活性蛋白C,蛋白S和组织因子通路抑制剂合作抑制血栓激活
Xian Li1, Xiaohong Song1, Dlovan F D Mahmood1
1Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, United States of America.
Thrombosis research
|September 3, 2023
概括
抗凝血剂组织因子通路抑制剂α (TFPIα) 和活性蛋白C (APC) 最好一起工作以抑制血栓生成. 血小板保护前热血酶,这表明血块中具有前凝剂作用.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 血栓素对于血液凝固至关重要,但其过量会导致血栓事件.
- 血栓激酶复合体 (FXa和FVa) 产生血栓.
- 现有的抗凝剂 (TFPIα,APC,PS) 单独显示出对前列血栓酶的有效性有限.
研究的目的:
- 研究TPFIα,APC和PS在抑制血栓生成中的协同作用.
- 阐明组合抗凝剂抑制前激素酶的机制.
主要方法:
- 使用纯化蛋白质和基于等离子体的系统进行实验.
- 测试用于测量血栓激活和抗凝剂活性.
- 利用抗体阻止特定的抗凝路途径.
主要成果:
- TFPIα在血中表现出增强的抗凝剂活性与APC和PS.
- TFPIα,APC和PS一起通过纯化的前激素酶抑制了血栓激活.
- FXa保护了FVa免受APC的影响,但TFPIα逆转了这一效应.
- 血小板组装原酶仍然对TFPIα,APC和PS的抑制具有抗性.
结论:
- 建议使用针对FXa和FVa的联合抑制模型来降低调节血栓激活.
- 这种协同的抗凝剂机制在血小板凝块之外是有效的.
- 血小板为前激素酶提供了一个保护性环境,促进血块内的前凝状态.
相关概念视频
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
749
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
749
01:16Clot Retraction and Fibrinolysis
6.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.4K
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:09Coagulation
7.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.1K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K